## Wednesday, February 28th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30-5:30 pm</td>
<td>Melanoma Advocates &amp; Foundations Forum (invitation only)</td>
<td>Salon II</td>
</tr>
<tr>
<td>4:00-8:00 pm</td>
<td>Registration open</td>
<td>Foyer of Salon III</td>
</tr>
<tr>
<td>6:00-7:30 pm</td>
<td>Opening Reception</td>
<td>Salon III</td>
</tr>
</tbody>
</table>

## Thursday, March 1st

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am-6:00 pm</td>
<td>Registration</td>
<td>Outside of Salon Ballroom</td>
</tr>
<tr>
<td>7:00-8:15 am</td>
<td>General Breakfast</td>
<td>Salon III</td>
</tr>
<tr>
<td>7:00-8:15 am</td>
<td>Young Investigators Breakfast (by invitation only)</td>
<td>Plaza Ballroom</td>
</tr>
<tr>
<td>8:30-8:45 am</td>
<td>Opening Remarks Day 1</td>
<td>Salon I &amp; II</td>
</tr>
<tr>
<td></td>
<td>Michael Kaplan, MRA President &amp; CEO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Louise Perkins, MRA Chief Science Officer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Samantha Stinchcomb, Wayne Stinchcomb Big Orange Foundation</td>
<td></td>
</tr>
<tr>
<td>8:45-9:15 am</td>
<td>Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Suzanne Topalian, Johns Hopkins University: A decade of progress in melanoma</td>
<td></td>
</tr>
<tr>
<td>9:15-11:10 am</td>
<td>Session 1: New approaches and tools for predicting efficacy: immunotherapy and beyond</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Jennifer Wargo</td>
<td></td>
</tr>
<tr>
<td>9:15-9:40</td>
<td>Kai Wucherpfennig, Dana-Farber Cancer Institute: Human anti-MICA monoclonal antibodies for melanoma immunotherapy</td>
<td></td>
</tr>
<tr>
<td>9:40-10:05</td>
<td>Marisol Soengas, Spanish National Cancer Research Center (CNIO): Imaging and targeting dormant and pro-metastatic melanoma lesions in vivo</td>
<td></td>
</tr>
<tr>
<td>10:05-10:25</td>
<td>Iwei Yeh, University of California, San Francisco: Activating β-catenin mutations cooperate with BRAFV600E to promote invasion</td>
<td></td>
</tr>
<tr>
<td>10:25-10:45 am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45-11:10</td>
<td>Yvonne Saenger, Columbia University: Combination immunotherapy leads to decreased tumor growth, improved survival and intratumoral immune infiltration in transgenic murine model of melanoma</td>
<td></td>
</tr>
</tbody>
</table>
11:10 am-12:00 pm  | Session 2: Microbial influences on immunotherapy efficacy  
Chair: Marisol Soengas

11:10-11:35  | Tom Gajewski, University of Chicago: The commensal microbiota as a new variable impacting cancer immunotherapy

11:35-12:00  | Jennifer Wargo, MD Anderson Cancer Center: Profiling the microbiome to predict immunotherapy efficacy

12:00-12:10 pm  | Transition to lunch

12:10-1:15 pm  | Lunch and Panel Discussion
Salon III
The changing landscape of melanoma
Moderator: Elliott Sigal, MRA Board of Directors
Panelist: Richard Pazdur, Oncology Center of Excellence, FDA
Panelist: Marc Theoret, Oncology Center of Excellence, FDA
Panelist: Nageatte Ibrahim, Merck
Panelist: David Feltquate, Bristol-Myers Squibb
Panelist: Lynn Schuchter, University of Pennsylvania

1:15-1:30 pm  | Transition to room

1:30-3:00 pm  | Session 3: Melanoma metastasis
Chair: Robert Vonderheide

1:30-1:55  | Michael Davies, MD Anderson Cancer Center: Targeting BRAF mutant brain metastases

1:55-2:15  | Manuel Valiente, Spanish National Cancer Research Center (CNIO): Blocking brain metastasis by targeting the microenvironment

2:15-2:35  | Lucia Jilaveanu, Yale University: Response to PD-1 inhibitors in melanoma patients with brain metastases

2:35-3:00  | Robert Vonderheide, University of Pennsylvania: Radiation and immune checkpoint blockade from mechanism to patients

3:00-3:20 pm  | Break

3:20-5:00 pm  | Session 4: New targets for melanoma
Chair: Ido Amit

3:20-3:45  | F. Stephen Hodi, Dana-Farber Cancer Institute: Combined CTLA-4 and angiopoietin-2 blockade in advanced melanoma patients

3:45-4:05  | Niroshana Anandasabapathy, Weill Cornell Medical School: Tissue immune differentiation reveals new pathways of melanoma escape

4:05-4:30  | Michal Lotem, Hadassah Medical Organization: Mechanism of action of SLAMF6 and its potential role in immunotherapy
4:30-4:55  Ido Amit, Weizmann Institute of Science: Single cell analysis and perturbation of the tumor-immune ecosystem

4:55-5:00  Closing Remarks Day 1
Kristen Mueller, MRA Scientific Program Director

6:30-9:00 pm  Reception and Dinner.................................................................Teddy & the Bully Bar*
Dress: Casual  1200 19th Street, NW, (202) 872-8700
Reception: 6:30-7:00 pm; Dinner: 7:15 pm

*6:15-7:00 pm: Transportation provided to Teddy & Bully Bar; Shuttles will depart from the circular drive outside the hotel lobby. Upon exiting the hotel, bear to your right and shuttles will be stationed in the breezeway between the hotel and art gallery on the property.

Friday, March 2nd

6:30-10:00 am  Registration open.........................................................Outside Salon Ballroom

7:00-8:30 am  General Breakfast..................................................................Salon III

7:00-8:30 am  Industry Roundtable Breakfast (by invitation only)........Plaza Ballroom

8:40-8:45 am  Opening Remarks Day 2 .................................................Salon I & II
Kristen Mueller, MRA Scientific Program Director

8:45-11:25 am  Session 5: New strategies in preventing and treating melanoma
Chair: Lewis Cantley

8:45-9:10  Georgina Long, Melanoma Institute Australia, University of Sydney: Adjuvant therapy for melanoma

9:10-9:30  Steve Barthel, Brigham and Women’s Hospital: Melanoma cell-intrinsic Tim-3: An unexpected variable in cancer immunotherapy?

9:30-9:50  Amanda Lund, Oregon Health & Science University: Lymphatic vessels and T cell-inflammation in melanoma

9:50-10:15  Boris Bastian, University of California, San Francisco: Structure and expression level of BRAF fusion kinases affect drug response

10:15-10:35 am  Break

10:35-11:00  Susan Swetter, Stanford University: Artificial intelligence (AI) for cutaneous melanoma detection

11:00-11:25  Emily Bernstein, Icahn School of Medicine at Mount Sinai: Harnessing the epigenome for melanoma oncogene discovery

11:25-11:55  Lecture
Lewis Cantley, Weill Cornell Medical School: Development of AMPK activators for treatment of melanoma
11:55-12:35 pm  Panel Discussion
A decade of MRA: Funding for the future
Moderator: Margaret Anderson, MRA Board of Directors
Panelist: Debra Black, MRA Board Chair and Co-founder
Panelist: Georgina Long, Melanoma Institute Australia, University of Sydney
Panelist: Richard Marais, Cancer Research UK Manchester Institute
Panelist: Suzanne Topalian, Johns Hopkins University, MRA Board of Directors
Panelist: Jedd Wolchok, Memorial Sloan Kettering Cancer Center

12:35-12:45 pm  Closing Remarks
Michael Kaplan, MRA President and CEO
Louise Perkins, MRA Chief Science Officer

12:45-2:00 pm  Lunch and Departures.................................................................Salon III